852 related articles for article (PubMed ID: 11900213)
21. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
Meng FY; Yang LJ; Xu B; Liu XL; Zheng WY; Zhang Y; Huang F; Sun J; Liu QF
Ai Zheng; 2003 Dec; 22(12):1330-3. PubMed ID: 14693062
[TBL] [Abstract][Full Text] [Related]
22. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Tsimberidou AM; Kantarjian HM; Cortes J; Thomas DA; Faderl S; Garcia-Manero G; Verstovsek S; Ferrajoli A; Wierda W; Alvarado Y; O'Brien SM; Albitar M; Keating MJ; Giles FJ
Cancer; 2003 Apr; 97(7):1711-20. PubMed ID: 12655528
[TBL] [Abstract][Full Text] [Related]
23. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia.
Pui CH; Boyett JM; Hughes WT; Rivera GK; Hancock ML; Sandlund JT; Synold T; Relling MV; Ribeiro RC; Crist WM; Evans WE
N Engl J Med; 1997 Jun; 336(25):1781-7. PubMed ID: 9187068
[TBL] [Abstract][Full Text] [Related]
24. Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas.
Hawkins DS; Felgenhauer J; Park J; Kreissman S; Thomson B; Douglas J; Rowley SD; Gooley T; Sanders JE; Pendergrass TW
Cancer; 2002 Sep; 95(6):1354-65. PubMed ID: 12216105
[TBL] [Abstract][Full Text] [Related]
25. Multicenter analysis of treatment outcomes in adult patients with lymphoblastic lymphoma who received hyper-CVAD induction followed by hematopoietic stem cell transplantation.
Jeong SH; Moon JH; Kim JS; Yang DH; Park Y; Cho SG; Kwak JY; Eom HS; Won JH; Hong JS; Oh SY; Lee HS; Kim SJ
Ann Hematol; 2015 Apr; 94(4):617-25. PubMed ID: 25465233
[TBL] [Abstract][Full Text] [Related]
26. A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma.
Sawka CA; Shepherd FA; Franssen E; Brandwein J; Dotten DA; Routy JP; Walker IR; St-Louis J; Taylor M; Arts K; Crump M; Foote M
Biotechnol Annu Rev; 2005; 11():381-9. PubMed ID: 16216784
[TBL] [Abstract][Full Text] [Related]
27. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.
Kantarjian HM; O'Brien S; Smith TL; Cortes J; Giles FJ; Beran M; Pierce S; Huh Y; Andreeff M; Koller C; Ha CS; Keating MJ; Murphy S; Freireich EJ
J Clin Oncol; 2000 Feb; 18(3):547-61. PubMed ID: 10653870
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness of modified hyper-CVAD chemotherapy regimen in the treatment of adult acute lymphoblastic leukemia: a retrospective experience.
Jalaeikhoo H; Rajaeinejad M; Keyhani M; Zokaasadi M; Dehghani Firoozabadi MM
Cancer Med; 2018 Mar; 7(3):594-599. PubMed ID: 29383863
[TBL] [Abstract][Full Text] [Related]
29. Prolonged haematological toxicity from the hyper-CVAD regimen: manifestations, frequency, and natural history in a cohort of 125 consecutive patients.
Gill S; Lane SW; Crawford J; Cull G; Joske D; Marlton P; Mollee PN; Prince HM; Seymour JF
Ann Hematol; 2008 Sep; 87(9):727-34. PubMed ID: 18401583
[TBL] [Abstract][Full Text] [Related]
30. Prospective randomized trial to evaluate two delayed granulocyte colony stimulating factor administration schedules after high-dose cytarabine therapy in adult patients with acute lymphoblastic leukemia.
Hofmann WK; Seipelt G; Langenhan S; Reutzel R; Schott D; Schoeffski O; Illiger HJ; Hartmann F; Balleisen L; Franke A; Fiedler F; Huber C; Rasche H; Bergmann L; Ganser A; Pott C; Pasold R; Rudolph C; Ottmann OG; Gökbuget N; Hoelzer D
Ann Hematol; 2002 Oct; 81(10):570-4. PubMed ID: 12424538
[TBL] [Abstract][Full Text] [Related]
31. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
Tedeschi A; Montillo M; Strocchi E; Cafro AM; Tresoldi E; Intropido L; Nichelatti M; Marbello L; Baratè C; Camaggi CM; Morra E
Cancer Chemother Pharmacol; 2007 May; 59(6):771-9. PubMed ID: 17256136
[TBL] [Abstract][Full Text] [Related]
32. [Plasma cell leukemia induced to complete remission with negative minimal residual disease by qualitative PCR analysis after hyper-CVAD and high-dose melphalan followed by autologous peripheral blood stem cell transplantation].
Hosono N; Yamauchi T; Nakamura T; Yamashita T; Ueda T
Gan To Kagaku Ryoho; 2008 Mar; 35(3):533-7. PubMed ID: 18347412
[TBL] [Abstract][Full Text] [Related]
33. [Feasibility of a cyclophosphamide methotrexate and 5-fluorouracil regime intravenously administered with and without granulocyte-colony stimulating factor in surgically treated breast carcinoma].
Garrone O; Del Mastro L; Mariani GL; Ardizzoni A; Venturini M; Rosso R
Minerva Med; 1993 Sep; 84(9):467-72. PubMed ID: 7504219
[TBL] [Abstract][Full Text] [Related]
34. Intensive sequential chemotherapy with hematopoietic growth factor support for non-Hodgkin lymphoma in patients infected with the human immunodeficiency virus.
Costello RT; Zerazhi H; Charbonnier A; de Colella JM; Alzieu C; Poizot-Martin I; Cohen R; Bardou VJ; Xerri L; Olive D; Nezri M; Lepeu G; Gastaut JA
Cancer; 2004 Feb; 100(4):667-76. PubMed ID: 14770420
[TBL] [Abstract][Full Text] [Related]
35. Intensive salvage chemotherapy for primary refractory or first relapsed adult acute lymphoblastic leukemia: results of a prospective trial.
Martino R; Bellido M; Brunet S; Altés A; Sureda A; Guárdia R; Aventín A; Nomdedéu JF; Domingo-Albós A; Sierra J
Haematologica; 1999 Jun; 84(6):505-10. PubMed ID: 10366793
[TBL] [Abstract][Full Text] [Related]
36. [Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma].
Luo SK; Li J; Hong WD; Zhao Y; Tong XZ
Ai Zheng; 2005 Dec; 24(12):1518-21. PubMed ID: 16351805
[TBL] [Abstract][Full Text] [Related]
37. Persistence of peripheral blood and bone marrow blasts during remission induction in adult acute lymphoblastic leukemia confers a poor prognosis depending on treatment intensity.
Cortes J; Fayad L; O'Brien S; Keating M; Kantarjian H
Clin Cancer Res; 1999 Sep; 5(9):2491-7. PubMed ID: 10499624
[TBL] [Abstract][Full Text] [Related]
38. Granulocyte-colony stimulating factor and multiple cycles of strongly myelosuppressive alkylator-based combination chemotherapy in children with neuroblastoma.
Kushner BH; Heller G; Kramer K; Cheung NK
Cancer; 2000 Nov; 89(10):2122-30. PubMed ID: 11066054
[TBL] [Abstract][Full Text] [Related]
39. Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine.
Garcia M; Romaguera JE; Inamdar KV; Rassidakis GZ; Medeiros LJ
Cancer; 2009 Mar; 115(5):1041-8. PubMed ID: 19170236
[TBL] [Abstract][Full Text] [Related]
40. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
